CC-122 (Avadomide)also belongs to the CELMoD class of drugs, which can induce the degradation of IKZF1 and IKZF3 through the proteasome pathway (124), exhibiting anti-lymphoma, anti-angiogenesis, and immunomodulatory effects, making it a promising new-generation therapeutic agent for the treatment of non-Hodgkin’s lymphoma (NHL) (125–127). This evidence concerns the gene IKZF1 and non-Hodgkin lymphoma.